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Biological clockGlucocorticoid (GC) is an adrenal steroid hormone that controls a variety of physiological processes such as
metabolism, immune response, cardiovascular activity, and brain function. In addition to GC induction in
response to stress, even in relatively undisturbed states its circulating level is subjected to a robust daily
variation with a peak around the onset of the active period of the day. It has long been believed that the
synthesis and secretion of GC are primarily regulated by the hypothalamus–pituitary–adrenal (HPA)
neuroendocrine axis. However, recent chronobiological research strongly supports the idea that multiple
regulatory mechanisms along with the classical HPA neuroendocrine axis underlie the diurnal rhythm of
circulating GC. Most notably, recent studies demonstrate that the molecular circadian clockwork is heavily
involved in the daily GC rhythm at multiple levels. The daily GC rhythm is implicated in various human
diseases accompanied by abnormal GC levels. Patients with such diseases frequently show a blunted GC
rhythmicity and, more importantly, circadian rhythm-related symptoms. In this review, we focus on recent
advances in the understanding of the circadian regulation of adrenal GC and its implications in human health
and disease.82 2 884 6560.
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Circadian rhythms are comprised of a ubiquitous biological
oscillation of approximately 24-h periods that are highly conserved
from cyanobacteria to humans. This daily rhythm is not a simple
response to alternating changes of day and night. It arises from an
innate and genetically operated timekeeping system referred to as a
“biological clock” [1,2]. This internal timekeeping system allows
organisms to anticipate and prepare for changes in their physical
environments, thereby enabling them to behave appropriately at the
right time of day. The biological clock also greatly contributes to
ensuring that certain physiological processes take place in coordina-
tion with others [3]. In mammals, the suprachiasmatic nucleus (SCN)
of the anterior hypothalamus functions as the master circadian
pacemaker, driving overt circadian rhythms such as the rest-activity
cycle, daily variations in metabolism and body temperature, and the
rhythmic secretion of hormones [4].
Glucocorticoid (GC) is an adrenal steroid hormone that plays a
crucial role in the adaptive responses to various types of stress and is
under the control of the hypothalamus–pituitary–adrenal gland
(HPA) neuroendocrine axis. In addition to its stress reactivity, robust
daily variation in the circulating level is another key feature of this
hormone. It is widely accepted that the daily GC rhythm is also under
the control of circadian timing because its rhythmicity is completelyblunted by disruption of the SCN harboring the master oscillator [5]. It
is well known that chronic dysregulation of GC, i.e. either hyper- or
hyposecretion, induces the onset of diverse pathological conditions by
disrupting carbohydrate and lipid metabolism, immune response,
cardiovascular activity, mood, and cognitive/brain functions. A
growing body of evidence suggests that not only the level of
circulating GC but also its rhythmic activity plays a signiﬁcant role
in human health and disease [6,7]. Therefore, understanding the
regulatory mechanisms of the daily GC rhythm and its physiological
relevance can provide novel insight into both the molecular basis and
clinical treatment of human diseases involving abnormal GC secre-
tion. Here, we review recent progress in circadian clock research and
focus on the roles of the circadian timing system in the daily GC
rhythm and its clinical implications.
2. Circadian timing system and molecular clockwork
2.1. The mammalian circadian clockwork
Because of the earth's rotation, almost all organisms function
under 24-h day–night cycles. To adapt to and anticipate external daily
cycles, organisms have evolved an internal timekeeping system. This
daily timekeeping system is referred to as the “circadian clock” from
the Latin “circa diem,”which literally meaning “approximately a day.”
It is both autonomous and self-sustainable but is also continuously
entrained by external time cues called “zeitgeber.” The mammalian
circadian timing system consists of 3 basic components: 1) input
signals (environmental cues), 2) a circadian oscillator as an intrinsic
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generally been considered to be the central circadian oscillator both
anatomically and functionally; it receives photic information from the
eyes via the retino-hypothalamic tract, and then synchronizes the
circadian timing system with environmental time [4,8]. This notion is
strongly supported by ﬁndings that selective ablation of the SCN leads
to a complete loss of circadian rhythmicity, whereas transplantation
of an intact SCN into arrhythmic mutant animals restores circadian
rhythmicity [9,10]. The circadian rhythm generated in the SCN is
believed to be converted into neuronal or hormonal signals that affect
metabolic processes, physiology and behavior (Fig. 1).
The autonomous and self-sustaining nature of the circadian timing
system primarily depends on the presence of a genetic mechanism
known as the molecular circadian clockwork. “Clock genes” are
required for the generation and maintenance of the circadian rhythm
in an organism and even within individual cells [11,12]. The clock
genes and their gene products cooperatively promote rhythmic gene
expression by two interlocked positive and negative transcription/
translation feedback loops that are core and auxiliary (Fig. 2). In the
principal or core feedback loop, members of the basic helix–loop–
helix–Period-ARNT-single-minded (bHLH-PAS) transcription factor
superfamily, such as CLOCK and BMAL1, form heterodimers to activate
the transcription of their target genes containing E-box elements in
the cis-regulatory regions of those genes [13–15]. These target genes
include their negative regulators such as the Periods (PERs: PER1,
PER2 and PER3) and the Cryptochromes (CRYs: CRY1 and CRY2). The
concentration of BMAL1 is adjusted by an auxiliary or stabilizingFig. 1. Hierarchical organization of the mammalian circadian timing system. The
suprachiasmatic nucleus (SCN), which resides in the ventral hypothalamus, functions
as the central clock responsible for the coordination of multiple clock networks in the
body. It communicates with and synchronizes local clockworks in other tissues,
including both peripheral tissues and extra-SCN regions of the brain. Examination of the
tissue-speciﬁcmodulation of the clockmachinery revealed the autonomous role of each
local clock (also see the text), and the adrenal peripheral clock in particular is involved
in the daily rhythms of GC and exerts an impact on the synchronization of other
peripheral clocks and the regulation of physiological systems, including metabolism.feedback loop formed by the clock-controlled nuclear receptors REV-
ERBα and RORα [16–19]. The self-sustaining feedback loops described
in Fig. 2 constitute the circadian molecular clock machinery in an
approximate 24-h period.
In addition to core regulation at the level of transcription/
translation, circadian clock proteins are also subjected to extensive
post-translational modiﬁcations that appear to control their protein
stability, nuclear localization and functional activity. For example,
casein kinase 1ε and δ are known to be critical factors that regulate the
turnover of PERs and CRYs in mammals [20–22]. BMAL1 is
rhythmically sumoylated in vivo and the sumoylation promotes its
interaction with CLOCK, exclusive nuclear accumulation in promye-
locytic leukemia (PML) nuclear bodies, transactivation and ubiquitin-
dependent degradation [23–25]. BMAL1 is also regulated by acetyla-
tion so as to have a role in the maintenance of circadian rhythmicity
[26]. In addition, the Ca2+-dependent protein kinase C (PKC)-
mediated phosphorylation of CLOCK and subsequent recruitment of
cofactors to the CLOCK/BMAL1 heterodimer appear to be important
for the phase resetting of the mammalian circadian clock [27,28].
Post-translational regulation of the clock proteins and its functional
signiﬁcance are extensively reviewed elsewhere [11,12].
2.2. Central and peripheral clocks in rhythmic physiological outputs
The mammalian circadian system is organized in a hierarchical
manner. At the top of the mammalian circadian timing system, the
SCN is composed of densely packed neurons that have self-sustaining
rhythmic capacity [29]. It is striking that not only the SCN but also
most tissues and peripheral organs express their own clock genes. It
has been shown that even cultured cells in vitro retain their
rhythmicity at the single cell level; thus, a high concentration of
serum or synthetic GC agonist is able to synchronize individual
rhythms so as to exhibit a robust cyclic clock gene expression at the
cell population level [30–33]. Furthermore, it has been established
that most mammalian cells possess their own circadian clocks. These
clocks have a molecular makeup similar to that in SCN pacemaker
neurons, but are referred to as peripheral or local clocks to distinguish
them from the master clock in the SCN. Therefore, the SCN serves as
the center for harmonizing the circadian rhythm in mammals by
coordinating the rhythms of the peripheral clocks scattered through-
out the body (Fig. 1). The SCN maintains continuous communication
with the peripheral clocks through a variety of neural and humoral
signals [34]. In addition to the time information transmitted by the
SCN, other zeitgebers, such as feeding times and body temperature
rhythms, play an important role in the resetting of these peripheral
timekeepers [4]. In this context, it should be noted that GC is an
attractive candidate for the key hormonal link between the SCN and
the peripheral clocks. This issue will be discussed in a later section of
the present article.
A variety of physiological processes in mammals, including the
sleep–wake cycle, body temperature, renal plasma ﬂow and cardio-
vascular activity are inﬂuenced by circadian regulation [3]. Although
the rhythmic features of these physiological processes require SCN
involvement, the presence of ubiquitous peripheral oscillators
strongly supports their contribution to the manifestation of circadian
rhythms in a variety of cellular processes. Considerable evidence has
been obtained from transcriptome-proﬁling studies. For example,
5–10% of allmRNA species display a circadian expressionpattern in the
liver [35–38]. A comparison of the transcriptome proﬁles in different
tissues [38] revealed that most circadian transcripts are expressed in a
tissue-speciﬁc fashion, which is in keeping with the idea that different
functions are controlled by different tissues' own local circadian
clockwork. However, the roles of the peripheral clocks and the central
pacemaker in governing the circadian functions in a given organ are
rarely distinguished. In this context, selective modulation of certain
peripheral clock machinery has been recently examined for the
Fig. 2.Molecular circadian clockwork. The mammalian circadian oscillator is composed of 2 interlocking transcriptional/translational feedback loops: core and auxiliary. The CLOCK/
BMAL1 heterodimer, the integral component of the core loop, induces E-box-mediated transcription of the negative regulators Periods (PERs) and Cryptochromes (CRYs).
Accumulated PER and CRY proteins intensively repress E-box-mediated transcription until their levels have sufﬁciently decreased. Additionally, CLOCK and BMAL1 also control the
transcription of nuclear receptors RORα and Rev-erbα, which modulate Bmal1mRNA levels by competitive actions on the RRE element residing in the Bmal1 promoter. Collectively,
the cycling of the clock components also determines the levels of the clock-controlled gene (CCGs) by transcription via the E-box and/or RRE to achieve their oscillating patterns and
thus to generate rhythmic physiological output.
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Takahashi et al. investigated the functional rescue of certain tissues in
BMAL1 knockout mice, thus showing the requirement of brain BMAL1
activation for circadian behavioral rhythms [39]. In another study,
liver-speciﬁc abrogation of Bmal1 resulted in a dysfunction in glucose
and lipid metabolism [40,41] as well as pancreatic disruption of the
local clock that led to diabetes mellitus because of defective β-cell
function [42]. Endothelial BMAL1 appears to affect the response to
thrombogenic stimuli and blood pressure in the cardiovascular system
[43]. Notably, disruption of the adrenal local clock inﬂuenced the
daily GC proﬁles [44,45], indicating the importance of the adrenal
peripheral clock in the robust circadian rhythm of the steroid
hormone.
3. Neuroendocrine regulation of the adrenal GC
3.1. HPA axis and physiological roles of GC
The HPA axis is a major neuroendocrine circuit of the stress
response system, and adrenal GC synthesis and secretion are known
to be tightly regulated by upstream hormones secreted from the
hypothalamus and the pituitary (Fig. 3). Brieﬂy, certain neurochem-
ical signals reach the hypothalamus and then neurons in the
paraventricular nucleus (PVN) of the hypothalamus release cortico-
trophin-releasing hormone (CRH) and arginine vasopressin (AVP) to
induce adrenocorticotropic hormone (ACTH) synthesis and secretion
from the pituitary. ACTH then induces adrenal synthesis and secretion
of GC, which interacts with speciﬁc receptors in various target tissues
in the brain and periphery. Circulating GC ultimately turns off the HPA
neuroendocrine activity and restores a steady state via negative
feedback [46].
As a ﬁnal effector of the stress-responsive HPA neuroendocrine
axis, GC exerts widespread effects in the body to maintain
homeostasis and enable the organism to prepare to respond to and
cope with physical and emotional stresses [47]. For examples, GCpromotes the breakdown of carbohydrate and protein and modulates
lipid deposition and breakdown. GC is also an important regulator in
numerous immune and inﬂammatory responses [48]. Furthermore, it
raises blood pressure, has diverse effects on bone, elicits both positive
and negative effects on cell growth, and is proapoptotic in certain cell
types, including certain neuronal cells. In addition to providing
negative feedback to the HPA axis, GC inﬂuences both neuronal and
glial cells in the central nervous system (CNS) to mediate important
organizational events in the developing brain and neural plasticity
and degeneration in adulthood. Other central inﬂuences include
changes in mood and behavior, the modulation of food intake, body
temperature and nociception [49].
3.2. Adrenal GC biosynthesis
GC is mainly synthesized from a subset of adrenocortical cells in
response to ACTH by the steroidogenic processing of cholesterol
(Fig. 4). The mammalian adrenal cortex is composed of cells that are
segregated into separate zones with distinct functions, the zona
glomerulosa (ZG), zona fasciculata (ZF) and zona reticularis (ZR), and
distinct sets of steroidogenic genes are expressed in each zone [50].
GC is mainly produced in the ZF, where the ACTH receptor (ACTHR;
melanocortin receptor 2, MC2R) is also highly expressed. During
activation of the HPA axis, ACTH binds to the ACTHR, activates
heterotrimeric Gs protein, and subsequently stimulates adenylyl
cyclase [51]. Intracellular cAMP then activates protein kinase A
(PKA) nuclear transcription factors, such as cAMP response element
(CRE) binding protein (CREB) and CRE modulator (CREM). These
transcription factors modulate the expression of genes involved in
adrenal GC biosynthesis by binding to the CRE residing in the
promoter regions of those genes [52,53].
Various sets of steroidogenic genes are known to be involved
in adrenal GC biosynthesis. First, cholesterol has to be transferred
from the cytosol to the inner mitochondrial membrane, where it
can be converted to pregnenolone, a common steroid precursor.
Fig. 3. Neuroendocrine regulation of adrenal GC and its physiological roles. GC is
primarily regulated by the hypothalamus–pituitary–adrenal gland (HPA) axis, a major
neuroendocrine circuit of the stress response system. When certain neurochemical
signals reach the hypothalamus as the result of stress or circadian input, a subset of
neurosecretory cells in the PVN of the hypothalamus releases CRH and AVP to induce
ACTH synthesis and secretion from the pituitary. ACTH then induces the adrenocortical
cells to produce and secrete GC. Circulating GC turns off the HPA neuroendocrine axis by
negative feedback mechanisms. In addition, GC exerts widespread actions in the body
as needed to restore and maintain various physiological homeostasis.
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which rapidly responds to hormonal stimulation, mediates the
delivery of cholesterol to the site of its ﬁrst enzymatic conversion of
cholesterol to pregnenolone by CYP11A1 (cholesterol side chain
cleavage monooxygenase). Hence, it constitutes a rate-limiting and
hormonally regulated step in steroidogenesis [52]. As described in
Fig. 4, pregnenolone is then subjected to the sequential actions of
several steroid hydrogenases (cytochrome P450 and heme-containing
proteins) and HSD3Bs (3β-hydroxysteroid dehydrogenases), ulti-
mately leading to GC production. CYP17 (17α-hydroxylase) is present
only in cortisol-producing species such as humans but not in
corticosterone-producing species such as rats and mice. It mediates
17α-hydroxylation and the cleavage of pregnenolone and progester-
one, thus constituting an additional pathway to cortisol biosynthesis
[54 and references therein].
4. Circadian regulation of GC biosynthesis and secretion
In addition to the response to stress, another key characteristic of
GC is its robust daily rhythm. Circulating GC levels are higher during
the activity period (day for diurnal species and night for nocturnal
species) and peak levels are linked to the beginning of the activity
period. Although the circadian rhythm of GC was reported several
decades ago, its molecular basis is still not fully understood. A growing
body of evidence resulting from recent advances in chronobiology has
shown that the daily variation is generated by multimodal forms of
regulation: the driving role of the SCN via the neuroendocrine axis
and autonomic nervous system as well as intrinsic mechanisms
involving the adrenal local clockwork appear to coincide with the
generation of the robust GC circadian rhythm in the circulation
[55,56]. Moreover, GC is considered as a key mediator for synchro-nicity of the circadian timing system [31]. In this section, we will
discuss the multiple regulatory mechanisms involved in the GC
circadian rhythm and its physiological relevance.4.1. SCN regulation occurs through the HPA axis and the autonomic
nervous system
The oscillatory proﬁles of circulating GC have primarily been
attributed to SCNmodulation of the HPA axis [57, Fig. 5]. Observations
that SCN abrogation eliminates the rhythms of plasma ACTH and GC
strongly support this notion. From the neuroanatomical aspect, SCN
pacemaker neurons seem to indirectly control the hypothalamic ACTH
secretagogue-producing neurons in the parvocellular division of the
PVN, projecting into the neighboring area of the PVN, the subpar-
aventricular zone, and the dorsomedial nucleus of the hypothalamus
[58]. Since the morning (trough) corticosterone (CS) levels are
reported to increase after SCN ablation in rats, strong inhibition of
basal GC release by the SCN seems evident [59]. AVP produced by a
subset of SCN neurons is considered one of the main neurotransmit-
ters mediating this inhibition [60]. However, several lines of evidence
suggest relatively restricted roles for the upstream hormonal
regulators of the HPA axis and the involvement of multiple inputs
into the adrenal gland. First, the daily rhythm in non-stress levels of
plasma CS usually displays a 5- to 10-fold higher amplitude from the
trough to peak levels in rodents, whereas the plasma ACTH rhythm is
relatively lower (up to 2-fold) or even frequently not signiﬁcantly
different throughout the day [44,61–64]. Despite only a modest
rhythm in ACTH, circulating CS levels exhibit a robust rhythm,
implying that additional regulation is likely involved. Second, the
plasma CS rhythm persists even in hypophysectomized rats receiving
ACTH pellets, demonstrating that the GC rhythm does not solely
depend on the rhythmic release of ACTH [65]. Third, it is also of
importance to note that even in the absence of SCN inhibitory signals,
plasma CS levels did not reach a peak level, and there was an apparent
discrepancy between the decrease in the inhibitory regulation from
the SCN and the afternoon increase in the circulating CS levels in rats
[59,66]. Thus, after a series of disinhibition experiments, Buijs et al.
suggested that additional signals with a delay of several hours after
the major inhibitory signal, but preceding the peak CS level, appear to
be required [66,67].
Recently, the inﬂuence of the central pacemaker in the SCN via
splanchnic nerve innervation to the adrenal gland has been reportedly
implicated [68–70, Fig. 5]. Diurnal control of GC secretion by this
autonomic SCN-adrenal pathway is supported by the following 2 lines
of evidence. First, sympathetic innervation of the adrenal gland
directly transmits light information to the gland that leads to
increased CS release, independent of HPA axis activation. Adrenaline
release by the adrenal medulla is responsible for the transmission of
the photic signal to the adrenal cortex [69]. Second, autonomic control
of the GC rhythm is related to modulation of adrenal sensitivity to
ACTH [68,70,71]. Adrenal responsiveness to ACTH in nocturnal
rodents exhibits a daily rhythm, with a higher sensitivity leading to
higher CS release in the evening [44,72]. It has been shown that the
sensitivity of the adrenal gland to ACTH stimulation is regulated via
splanchnic nerve innervations from the central clock of the hypotha-
lamic SCN [66–68,70]. However, discrepancies remain regarding the
daily alterations in adrenal responsiveness in the HPA axis. For
instance, it has been suggested that the diurnal changes in non-stress
CS involve splanchnic nerve integrity, but are not mediated by
differential responsiveness to ACTH [73]. More recently, it was also
shown that responses to mild stress in rats were not different
between the early light and dark phases, so there is some doubt about
the diurnal variation in the responsiveness of the HPA axis [74].
Furthermore, splanchnic nerve transection resulted in only a partial
decrease in peak CS circulation levels in rats, showing that SCN-
Fig. 4. Adrenal steroidogenesis and its hormonal regulation. GC is mainly synthesized in a subset of adrenocortical steroidogenic cells by successive enzymatic modiﬁcations of
cholesterol in the mitochondria. The transferring of cholesterol from the cytosol into mitochondrial compartments by StAR serves as the rate-limiting step. The ACTH secreted in
response to stress induces adrenal GC production by promoting steroidogenic gene expression through activation of the ACTHR/cAMP/PKA/CREB signaling cascades.
Fig. 5. Working model for the diurnal regulation of GC secretion and biosynthesis. Daily variations in circulating GC levels are achieved by multiple regulatory mechanisms. The
suprachiasmatic nucleus (SCN) regulates the adrenal rhythm by modulating HPA axis activity. The rhythmic production of arginine vasopressin by SCN neurons is involved in this
regulation. In an alternative pathway, splanchnic nerve innervation of the adrenal gland in the SCN-autonomic nervous system (ANS) contributes to circadian GC secretion as well as
a resetting of the adrenal local clock. In addition to the central mechanisms exerted by the master clock in the SCN, adrenal intrinsic mechanisms involving the adrenal local
clockwork underlie the GC rhythm. Although the adrenal local clock along with the ANSwas postulated to gate adrenal sensitivity to ACTH, it is more important that this local clock is
tightly linked with the steroidogenic pathway. Cyclic expression of StAR, a rate-limiting gene of steroid biosynthesis, is directly controlled by the CLOCK:BMAL1 heterodimer as an
adrenal gland-speciﬁc clock-controlled gene; consequently, the resulting daily oscillation in steroidogenesis contributes to the generation of the robust GC rhythm.
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the GC circadian rhythm [70].
4.2. Adrenal intrinsic mechanisms: the involvement of adrenal oscillator
The GC circadian rhythm is thus not fully explained by the SCN-
driven central mechanisms, as described above. Therefore, it is likely
that unidentiﬁed mechanisms remain, especially those that are
adrenal-intrinsic. Interestingly, restricted daytime feeding of noctur-
nal animals can dissociate the phases of the SCN central pacemaker
and other peripheral clocks, presumably by food-entrainable oscilla-
tors [75]; under this daytime feeding regime, the daily GC proﬁles are
split into 2 peaks each day [76,77], implying the presence of adrenal-
intrinsic mechanisms. In this regard, it is noteworthy that the adrenal
gland harbors its own circadian clockwork, as has been shown by
several independent groups [44,45,69,78]. The molecular clockwork
of the adrenocortical steroidogenic cells works autonomously, and it
can be entrained by the activation of the autonomic SCN-adrenal
pathway. Global analyses of the adrenal transcriptome support this
notion that this local clock machinery is linked to key cellular
pathways in the adrenal gland [44,69,78]. They include genes
encoding proteins involved in cholesterol biosynthesis and transport,
which may control the availability of the precursor for GC biosynthe-
sis. Several of the components implicated in ACTHR-signaling also
exhibit periodic expression, although it is still elusive whether they
are under the direct control of the local adrenal clock. Based on these
ﬁndings, as well as evidence obtained from the well-designed
transplantation experiments, Oster et al. proposed a “gating mecha-
nism”: the local clock machinery in the adrenal gland contributes to
the diurnal rhythm of GC by controlling the daily variation in the
adrenal sensitivity to ACTH [44]. Considering that splanchnic
innervation can entrain the adrenal local clockwork [69], it is plausible
that the adrenal clock mediates the autonomic SCN-adrenal pathway
so as to produce the robust GC rhythm (Fig. 5).
However, early pioneering works which demonstrated the
rhythmic nature of adrenal GC biosynthesis and secretion in
cultivated adrenal glands without any humoral or neural input
imply that a further adrenal-autonomous mechanism still remains
[79–81]. Cyclic accumulation of steroidogenic genes and accompa-
nying steroid production, which are linked with the adrenal
peripheral clock, would seem to be most likely candidates. Our
recent study demonstrated that StAR, a rate-limiting gene in the
regulation of steroidogenesis [82,83], is an adrenal-speciﬁc clock-
controlled gene, which resides under the transcriptional control of a
core clock component, the CLOCK:BMAL1 heterodimer [45]. It was
shown that StAR mediates molecular clock-evoked steroid produc-
tion, and its periodicity is found even under constant darkness. It
should be noted that both the adrenal StAR mRNA and protein levels
increase in the late daytime in accordance with the adrenal and
plasma CS proﬁles. This StAR expression proﬁle seems to be distinct
from that of other previously suggested steroidogenesis-related
genes, which reach their deduced peaks several hours after
subjective light-off time [44]. The transcriptional regulation of the
StAR gene expression by the local clockwork appears to be
evolutionarily conserved in both rodent and avian species [84,85].
Our recent unpublished observations indicate that human StAR
promoter activity is also regulated by the CLOCK:BMAL1 hetero-
dimer. Daily variations in adrenal StAR expression are maintained
even when the neural input into the gland is attenuated by
splanchnic denervation, supporting the idea that the adrenal local
clock is the primary determinant of cyclic StAR expression [70].
However, it is noteworthy that adrenal gland-speciﬁc ablation of the
molecular clockwork produces results in ﬂattened adrenal CS
content and a partially dampened circulating CS proﬁle in a mouse
model [45]. Therefore, it is reasonable to speculate that rhythmic
steroid production intrinsic to the gland contributes to the robustdaily rhythm in the circulating GC levels in cooperation with the
central modulation effected by hormonal and neural input (Fig. 5).
4.3. Rhythmic GC in the circadian timing system
Several features of the GC circadian rhythm strongly suggest its
potential importance in overall circadian physiology and metabolism.
For example, the diverse actions of GC on physiological processes
[86,87], such as the clock-resetting activity of the hormone [4,31],
support this notion. The daily GC rhythm is heavily involved in
behavioral rhythms; ﬂattening of the GC rhythm by either genetic
abrogation of the adrenal clock or the administration of exogenous GC
attenuates circadian locomotor activity [45,88,89]. Since the rhyth-
micity of the body temperature is not signiﬁcantly affected by this
dampened GC rhythm [45], GC may have an organizing effect on the
speciﬁc brain functions underlying the periodic locomotor behaviors,
presumably by coordinating motor functions or maintaining the
sleep–wake cycle [45,49]. Circadian cell proliferation rhythms in
many tissues are also candidates for the circadian output inﬂuenced
by GC [90]. Circadian cell cycle rhythms in zebraﬁsh larvae were
severely attenuated in the absence of GC signaling, implying a role of
the steroid hormone as a systemic input crucial for cell proliferation at
the right time [91], although homologous functions in mammalian
species have not yet been identiﬁed.
An acute administration of GC can induce phase synchronization in
a wide range of peripheral clocks both in vivo and in vitro [31]. Such
clock-resetting activity by GC can be also considered in terms of the
circadian cyclicity of the hormone. Indeed, an attenuated GC rhythm
leads to a blunted cyclic accumulation of Per1 mRNA in several
peripheral organs such as the liver, kidney, and pancreas, but not in
the SCN [45]. Conversely, chronic administration of a synthetic GC
completely abolished circadian Per1 expression in peripheral organs
by a mechanism associated with its constitutive overexpression in
spite of the presence of an intact molecular oscillator [88]. The
periodic clock gene expression in certain discrete brain regions also
requires rhythmic GC signaling, implying that even higher brain
functions can be directly inﬂuenced by the adrenal rhythm [89,92]. It
might be supposed that the GC circadian rhythm by itself can produce
the rhythmic physiological outputs from other tissues in a more direct
fashion via classical GC signaling, and thus contribute to the overt
pattern of the rhythms considering the observations that the
expression of at least 10% of all genes are inﬂuenced by GC [86].
Moreover, there are two GC receptor types, with distinctive afﬁnities
and capacities, and these are believed to be differentially activated at
the circadian peak and nadir of the circulating ligand levels [86]. This
idea is strongly supported by the observations that the rhythmic
expression of a large number of genes in the liver is more dependent
on an intact adrenal gland and/or GC signaling rather than the hepatic
oscillator [93,94]. Therefore, it is likely that the circulating GC rhythm
inﬂuences some number of gene cycling patterns, as well as periodic
metabolic activity and behavior by a more direct actions on them.
On the other hand, accumulating evidence also suggests that there
are stabilizing effects of GC on established physiological rhythms in
vivo. GC inhibits the daytime feeding-induced phase shift of
peripheral oscillators by GR-dependent mechanism in rats [77].
Ablation of the adrenal gland or GR expression in target tissues
facilitates phase dissociation of the peripheral clocks from the SCN
central clock. More importantly, GC exhibits stabilizing feedback
effects on the central rhythm during the resynchronization. Ablation
of the entire adrenal gland or the adrenal clock facilitated re-
entrainment of the SCN-driven behavioral rhythm to a shifted light–
dark cycle in a zeitgeber time-dependent manner [95,96]. Daily CS
oscillations in rats are involved in regulating the photic entrainment
of the locomotor activity rhythm [95]. Upon advancing the GC rhythm
by the application of metyrapone, a GC biosynthesis inhibitor, it
results in a faster re-entrainment of the locomotor rhythm in the same
Table 1
Altered daily cortisol rhythms in patients with Cushing's syndrome or chronic fatigue
syndrome.
Disease Patients Measurement Daily proﬁles References
Cushing's
syndrome
7 Plasma cortisol, 24 h No diurnal
rhythm
[130]
7 Plasma cortisol, 24 h No diurnal
rhythm
[131]
39 Late-night salivary
cortisol
Higher levels at
23:00 h
[132]
103 Plasma cortisol at
2 points
No difference
between 00:00
and 08:00 h
[133]
120 Late-night salivary
cortisol
Higher levels at
22:00 h
[134]
Chronic fatigue
syndrome
30 Serum cortisol Lower levels in
the morning
[135]
7 Plasma cortisol, 24 h Low peak levels [121]
14 Salivary cortisol in the
morning and evening
Lower levels [136]
587S. Chung et al. / Biochimica et Biophysica Acta 1812 (2011) 581–591direction, as revealed in a mouse model of jet lag [96]. Taken together,
it is most likely that rhythmic GC contributes to the circadian timing
system by harmonizing diverse circadian output pathways and
providing resistance to sporadic environmental changes so as to
avoid uncoordinated shifts.
5. Circadian rhythm of GC in human health and disease
Dysregulated GC secretion is responsible for numerous patholog-
ical conditions [7,46–49,86,87]. Alterations in its rhythmicity are
frequently found in many human diseases, including Cushing's
syndrome, mood disorders, Alzheimer's disease, and metabolic
syndrome [7,97–99]. Importance of rhythmic GC has been well
recognized in the course of its clinical applications; tonic replacement
at a constant dosage is not as successful as expected, and in fact is
related to cardiovascular mortality, disturbed daily glucose homeo-
stasis and bone loss [100]. Uncoupling of the ACTH and the GC levels
observed in the circadian regulation of the HPA axis is also an
important issue; such uncoupling during the phase of GC level
increase can arise from either autonomic or extrinsic causes. Notably,
mismatches between circulating ACTH and cortisol often occur in
conditions such as chronic fatigue syndrome, sepsis, post-traumatic
stress disorder, and some cases of alcoholism [101–103]. We will
brieﬂy review several of the human diseases closely related to GC
dysregulation and circadian rhythmicity.
5.1. Cushing's syndrome
Cushing's syndrome, a clinical syndrome of endogenous cortisol
excess due to various causes, occurs with a substantially high
prevalence. The long-term consequences of severe hypercortisolism
include diabetes mellitus, osteoporosis, bone fractures, hypertension,
dyslipidemia, recurrent infections, sleep disorder, and increased
mortality [7]. Mortality in Cushing's disease is usually 2–5 times
higher than expected in the matched control population [104–106],
and even mild hypercortisolism has harmful effects on long-term
health because of decreased insulin sensitivity and altered glucose
tolerance [107,108]. Cushing's syndrome can be separated into the
categories of ACTH-dependent and ACTH-independent. In ACTH-
dependent Cushing's syndrome, inappropriately high levels of plasma
ACTH secretion caused by corticotropin-producing tumors persistent-
ly stimulate the adrenal cortex. In contrast, excessive production of
cortisol by abnormal adrenocortical tissue induces ACTH-independent
Cushing's syndrome, suppressing the secretion of both CRH and ACTH
by a negative feedback mechanism [109].
It is well known that Cushing's syndrome is associated with a
disturbed circadian rhythm; patients with Cushing's syndrome show
increased basal cortisol levels as well as an altered daily rhythm
(Table 1 and references therein). Therefore, some diagnostic tests for
Cushing's syndrome are designed to evaluate the circadian rhythm of
cortisol, for instance, determination of the 24-hr free cortisol and late-
night cortisol levels [7 and Table 1]. Sleep disorders are another
circadian feature of Cushing's syndrome. They are associated with an
increased frequency of sleep apnea or sleep fragmentation [110,111].
These symptoms appear to be related to altered GC rhythms
[112,113], but the exact causes remain unclear.
The cAMP/PKA signaling pathway tends to be enhanced in adrenal
GC-producing cells in both ACTH-dependent and -independent
Cushing's syndrome. Excess ACTH strongly increases cAMP produc-
tion by adenylyl cyclase in association with its receptors, and
persistent activation of the PKA pathway induces the production
and secretion of cortisol from the adrenal gland [114]. In addition,
investigation of the molecular cause of bilateral adrenocortical
hyperplasia leading to ACTH-independent Cushing's syndrome
reveals certain prevalent mutations in the regulatory subunit type1-
α of protein kinase A (PRKAR1A) and phosphodiesterase-11A(PDE11A) [115]. These mutations reinforce cAMP/PKA signaling by
constitutive PKA activation and cAMP degradation blockade. In this
context, a recent publication which reported that rhythmic cAMP/PKA
signaling is a prerequisite for normal cycling and functioning of the
cellular clockwork is noteworthy [116]. It can, therefore be speculated
that the disruption of GC rhythmicity in Cushing's syndrome may
involve dysregulated cAMP/PKA signaling in many cases. This
possibility needs to be further investigated in the near future.
5.2. Adrenocortical insufﬁciency and GC replacement therapy
Adrenocortical insufﬁciency which arises from Addison's disease
(an autoimmune disorder causing degeneration of the adrenal cortex),
congenital adrenal hyperplasia (an inherited defect in adrenocortical
steroidogenesis) or certain pituitary diseases (secondary adrenal
insufﬁciency) is commonly characterized by vulnerability to stress,
white blood cell elevation, lymphoid tissue hypertrophy, hypotension,
mood disturbances, weight loss, and hypoglycemia [117]. Major
symptoms and signs of the diseases are mainly due to insufﬁcient
adrenal GC, and thus GC replacement therapy is commonly employed.
Although cortisol rhythmic activity is often observed in patients with
adrenal insufﬁciency, the amplitude of the cortisol rhythms is usually
dampened due to a reduction in the peak levels of circulating GC [118].
In this context, it should be noted that some symptoms of GC
insufﬁciency are closely related to circadian disorders; for example,
sleep disturbances in association with increased fatigue during the
daytime were reported [100]. Since simple replacement with a
constitutive dose of GC was not as effective at alleviating symptoms
as expected and often exacerbated cardiovascular and metabolic
disturbances [100,117], the rhythmic nature of cortisol has become an
important issue in the design of GC replacement therapy regimens.
Oral administration of conventional immediate-release hydrocor-
tisone (HC; the generic pharmaceutical name of cortisol) two or three
times a day is a widely accepted regimen to manage adrenal
insufﬁciency, in which dose is set higher in the morning and lower
in the evening to mimic daily cortisol rhythm. Although such
conventional HC replacements have some beneﬁt, the mortality and
morbidity risks are still higher than in the normal population
primarily due to a short half-life of the hormone in circulation.
Furthermore, the under-replacement of cortisol often leads to the
onset of malaise, hypotension, weight loss, abdominal pain, electro-
lyte abnormalities and an impaired stress response. On the other
hand, overdosing can result in Cushingoid symptoms such as glucose
intolerance, hypertension, cardiovascular disease and mood disorders
[100,119]. As a result, the ideal GC replacement therapy would mimic
the normal physiological state as closely as possible. Several
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more conveniently, delayed and sustained release oral formulations of
HC have been introduced over the past few years [100,120]. In
particular, an approach with a modiﬁed-release HC tablet has
emerged that allows a delayed and thus sustained rise in the
circulating HC level so as to reach its peak at approximately the
morning time of awakening when taken at nighttime [119,120].
Therefore, a better understanding of the rhythmic nature of GC and
the development of new drug-delivery technologies may provide
improved hormone replacement regimens for adrenal insufﬁciency,
which would be more simpliﬁed and efﬁcient to relieve symptoms,
but have less adverse effects on physiology.
5.3. Chronic fatigue syndrome
Chronic fatigue syndrome (CFS) is a disorder characterized by
profound disabling chronic fatigue in association with a number of
other symptoms. Operationally deﬁned, the fatigue should be severe
enough to cause a signiﬁcant loss of physical and social function for a
minimum of 6 months, and 4 of the following symptoms must also be
present: sleep disturbance, impaired concentration, muscle pain,
multijoint pain, headaches, post-exertional exacerbation of fatigue,
sore throat, tender lymph nodes and depression [101]. CFS is a
common and disabling problem that may be related to certain
psychosocial factors, but the nature of the pathophysiological
components of this disease remains unclear. In many cases, patients
with CFS exhibit alterations in the HPA axis, including mild
hypocortisolism and reinforced negative feedback (Table 1). Many
studies with serial measures of unstimulated cortisol in a variety of
biological ﬂuids have reported reduced cortisol levels, particularly the
peak levels, suggesting that the GC circadian rhythm can be
attenuated in a large proportion of CFS patients [101 and references
therein]. Reduced activity and sleep disturbance imply disruption of
behavioral rhythms, but daily variations of core body temperature and
pituitary hormone levels are surprisingly normal in CFS patients [121].
Although it is still debatable whether disturbed HPA function is a
cause or a consequence of CFS, the reported effectiveness of low-dose
GC therapy in CFS patients suggests that attenuated GCmay be related
to some of the syndromes to some degree [122]. Interestingly, these
features are comparable with the phenotypes observed in transgenic
mice with attenuated GC circadian rhythms because of adrenal-
speciﬁc abrogation of clock machinery: the mutant mice exhibited
dampened GC rhythms and hypo-locomotion during the activity
period, but a normal temperature rhythm [45].
5.4. Clinical consequences of environmentally disrupted GC rhythm
Common environmental stimuli such as those associated with
shift-work, sleep deprivation, night-time eating and jet lag can alter or
disrupt normal circadian physiology. In those cases, the body tries to
adapt to or endure such disruptions by adjusting the internal
timekeeping system, but chronic disruption may lead to persistent
dysregulation of the circadian timing system. For example, shift work
and night-time eating are strongly associated with the onset of
metabolic syndrome, a cluster of health risk factors characterized by
the impairment of carbohydrate and lipid metabolism and normal
functioning of adipose tissue and the cardiovascular, and hemostatic
systems [123]. Chronic jet lag may inﬂuence malignant tumor growth
[124] and even cognitive impairments associated with reduced brain
temporal lobe [125,126]. Accordingly, chronic desynchronization of
circadian rhythmicity in laboratory animals signiﬁcantly increases
mortality often by cardiomyopathic heart disease [127,128].
GC is one of the key factors in the pathogenesis of metabolic
syndrome, and its symptoms share many features with those of other
human disease related with dysregulation of GC, such as Cushing's
syndrome. In addition, several lines of evidence suggest that patientswith metabolic syndrome are characterized by hyperactivity of the
HPA axis, leading to hypercortisolism [129]. It is also of importance to
mention that increased cortisol levels are closely related with
cognitive deﬁcits in airline ﬂight crews repeatedly exposed to jet lag
[125,126]. As mentioned earlier, GC has an inﬂuence on circadian
outputs during the adaptation to new zeitgeber cues, including
changes in the light–dark schedule and feeding times. Therefore,
chronic disruption of the GC circadian rhythm may be involved in
both the adaptation/entrainment and pathophysiological conse-
quences of environmental disruption of the circadian timing system.
6. Conclusion
In conclusion, the current understanding of the circadian control of
the adrenal GC and human diseases related to disruptions of this
temporal regulation is here reviewed. Periodic GC secretion and
biosynthesis are tightly regulated by coincident multiple mechanisms
at different levels of the circadian timing system. The master clock in
the SCN directly drives the GC circadian rhythm both by modulating
the HPA neuroendocrine axis and via sympathetic splanchnic
innervation of the adrenal gland. However, a growing body of
evidence points to the importance of local clockwork in the adrenal
gland itself. The oscillating adrenal clock machinery plays a crucial
role in maintaining the rhythm by controlling the capacity and
responsiveness of adrenal GC secretion and biosynthesis to ACTH.
Therefore, the next questions are related to determining how these
multiple mechanisms are coordinated with the robust cyclicity of the
secretion of the hormone, and then how GC target cells sense and
process this rhythmic information. Another important question
regarding the GC rhythm concerns its role in physiology and
pathophysiology. Although the importance of the rhythmic GC has
been appreciated for some time, the speciﬁc physiological relevance
of the rhythm, particularly in human health and disease, remains to be
further elucidated. Recent advances in our knowledge on the
molecular and cellular basis of the GC circadian rhythm should help
provide novel insights and breakthroughs to resolve these as yet
outstanding issues.
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